Esperion Q3 2022 Earnings Report
Key Takeaways
Esperion reported a total revenue of $19.0 million for Q3 2022, a 32% increase compared to the same period in 2021. U.S. product revenue grew by 28% year-over-year, reaching $14.0 million. The company's net loss for the quarter was $55.1 million, with a reduced SG&A expenses by 36% year-over-year.
U.S. Net Product Revenue of NEXLETOL and NEXLIZET grew 28% Y/Y to $14.0 Million.
CLEAR Outcomes trial achieved last patient last visit in October, ensuring timely trial completion.
Topline results for the CLEAR Outcomes trial are expected in January 2023.
Selling, general and administrative expenses decreased by 36% year-over-year.
Esperion
Esperion
Esperion Revenue by Segment
Forward Guidance
The Company reaffirms its prior operational expense guidance. Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million. Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million. Esperion expects full-year 2022 operating expenses to be approximately $220 million to $240 million, inclusive of $25 million of non-cash, stock-based compensation expense.
Revenue & Expenses
Visualization of income flow from segment revenue to net income